Susquehanna International Group
CAI

Susquehanna International Group’s Caris Life Sciences CAI Stock Holding History

Susquehanna International Group’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.92M Buy
163,200
+45,300
+38% +$990K ﹤0.01% 5320
2025
Q4 		$3.18M Sell
117,900
-27,500
-19% -$775K ﹤0.01% 4781
2025
Q3 		$4.4M Buy
+145,400
New +$4.64M ﹤0.01% 4284

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Susquehanna International Group's CAI Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Caris Life Sciences (CAI) in Q1 2026: 53,066 shares worth $949K. The stake represents ﹤0.01% of the portfolio and ranks #8008 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in CAI as recently as Q3 2025.

Susquehanna International Group first reported a position in CAI in Q3 2025 and has held it in 2 quarters since. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Susquehanna International Group held 53,066 shares of Caris Life Sciences worth $949K as of Q1 2026.
  • Caris Life Sciences was a new Susquehanna International Group position in Q1 2026.
  • Caris Life Sciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8008 holding.
  • Susquehanna International Group first reported a position in Caris Life Sciences in Q3 2025 and has held it in 2 quarters since.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.